SLC5A2 and heart failure: Compared to previous meta-analyses that suggested no discernible difference among different SGLT2 inhibitors, this study showed that dapagliflozin might have similar but slightly favorable composite cardiovascular outcomes compared to empagliflozin and significantly lower risks of cardiovascular death and heart failure-related events [16, 17, 34, 35].